1022 related articles for article (PubMed ID: 11051233)
21. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
22. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394.
Grossman SA; O'Neill A; Grunnet M; Mehta M; Pearlman JL; Wagner H; Gilbert M; Newton HB; Hellman R;
J Clin Oncol; 2003 Apr; 21(8):1485-91. PubMed ID: 12697871
[TBL] [Abstract][Full Text] [Related]
23. High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients.
Fernández-Hidalgo OA; Vanaclocha V; Vieitez JM; Aristu JJ; Rebollo J; Gúrpide A; Aramendía JM; Moreno-Palanques R; Martín-Algarra S; Subirá ML; Brugarolas A
Bone Marrow Transplant; 1996 Jul; 18(1):143-9. PubMed ID: 8832007
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of radiotherapy after hyperbaric oxygenation with multiagent chemotherapy (procarbazine, nimustine, and vincristine) for high-grade gliomas: long-term results.
Ogawa K; Ishiuchi S; Inoue O; Yoshii Y; Saito A; Watanabe T; Iraha S; Toita T; Kakinohana Y; Ariga T; Kasuya G; Murayama S
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):732-8. PubMed ID: 21420247
[TBL] [Abstract][Full Text] [Related]
25. Radiochemotherapy of malignant glioma in adults. Clinical experiences.
Kortmann RD; Jeremic B; Weller M; Plasswilm L; Bamberg M
Strahlenther Onkol; 2003 Apr; 179(4):219-32. PubMed ID: 12707711
[TBL] [Abstract][Full Text] [Related]
26. Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors.
Levin VA; Chamberlain MC; Prados MD; Choucair AK; Berger MS; Silver P; Seager M; Gutin PH; Davis RL; Wilson CB
Cancer Treat Rep; 1987 May; 71(5):459-64. PubMed ID: 3105881
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
28. Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy.
Jennings MT; Cmelak A; Johnson MD; Moots PL; Pais R; Shyr Y
Pediatr Blood Cancer; 2004 Jul; 43(1):46-54. PubMed ID: 15170889
[TBL] [Abstract][Full Text] [Related]
29. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
Webre C; Shonka N; Smith L; Liu D; De Groot J
Anticancer Res; 2015 Oct; 35(10):5467-72. PubMed ID: 26408710
[TBL] [Abstract][Full Text] [Related]
30. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
Buckner JC; Ballman KV; Michalak JC; Burton GV; Cascino TL; Schomberg PJ; Hawkins RB; Scheithauer BW; Sandler HM; Marks RS; O'Fallon JR; ;
J Clin Oncol; 2006 Aug; 24(24):3871-9. PubMed ID: 16921039
[TBL] [Abstract][Full Text] [Related]
31. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
32. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
33. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M
BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083
[TBL] [Abstract][Full Text] [Related]
34. [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
Bouffet E; Mornex F; Jouvet A; Thiesse P; Mertens P; Helfre S; Sindou M; Bret P
Bull Cancer; 1997 Oct; 84(10):951-6. PubMed ID: 9435796
[TBL] [Abstract][Full Text] [Related]
35. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
36. [The effect of extent of tumor resection on the outcome of combined therapy in patients with glioblastoma multiforme].
Jeremić B; Grulicić D; Samardzić M; Antunović V; Joksimović M; Djurić Lj; Milicić B; Nikolić N
Srp Arh Celok Lek; 1997; 125(3-4):93-8. PubMed ID: 9221525
[TBL] [Abstract][Full Text] [Related]
37. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
Groves MD; Maor MH; Meyers C; Kyritsis AP; Jaeckle KA; Yung WK; Sawaya RE; Hess K; Bruner JM; Peterson P; Levin VA
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):127-35. PubMed ID: 10477016
[TBL] [Abstract][Full Text] [Related]
38. Chemoradiation and adjuvant chemotherapy for glioblastoma: why does so much therapy yield so little improvement in survival?
Loeffler JS; Shrieve DC; Coleman CN
Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):531-3. PubMed ID: 7673044
[No Abstract] [Full Text] [Related]
39. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
Shibui S; Narita Y; Mizusawa J; Beppu T; Ogasawara K; Sawamura Y; Kobayashi H; Nishikawa R; Mishima K; Muragaki Y; Maruyama T; Kuratsu J; Nakamura H; Kochi M; Minamida Y; Yamaki T; Kumabe T; Tominaga T; Kayama T; Sakurada K; Nagane M; Kobayashi K; Nakamura H; Ito T; Yazaki T; Sasaki H; Tanaka K; Takahashi H; Asai A; Todo T; Wakabayashi T; Takahashi J; Takano S; Fujimaki T; Sumi M; Miyakita Y; Nakazato Y; Sato A; Fukuda H; Nomura K
Cancer Chemother Pharmacol; 2013 Feb; 71(2):511-21. PubMed ID: 23228988
[TBL] [Abstract][Full Text] [Related]
40. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Levin VA; Silver P; Hannigan J; Wara WM; Gutin PH; Davis RL; Wilson CB
Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):321-4. PubMed ID: 2154418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]